BRISTOL MYERS SQUIBB CO

Bristol-Myers Squibb Company engages in the discovery, development, licensing, and commercialization of biopharmaceutical products. Its commercial portfolio and drug development pipeline encompass therapies across multiple therapeutic areas, including immunology, oncology, cardiovascular, hematology, and neuroscience. The company organizes its product offerings into growth brands—such as Opdivo, Orencia, Yervoy, Reblozyl, Breyanzi, Opdualag, Camzyos, Zeposia, Abecma, Sotyktu, Krazati, and Cobenfy—alongside legacy brands including Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel, and Abraxane. It generates revenue via direct net product sales, collaborative agreements, and royalties. Key customers and major wholesale distributors include McKesson Corporation, Cencora, and Cardinal Health.

The business operates internationally with commercial sales and collaborative presence across North America, Europe, and Asia. Specific geographic markets and foreign tax jurisdictions explicitly identified in the text include the United States, Switzerland, and Ireland, alongside commercial arrangements covering Japan, South Korea, and Taiwan. The provided text details regional rights and partnerships, but does not state the company's specific headquarters location, store count, founding year, or website domain.

Summary of the business section of Bristol Myers Squibb's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“Demographics : As of December 31, 2025, we had approximately 32,500 employees in 43 countries.”